Replies to post #82541 on PharmaCyte Biotech Inc (PMCB)

[rcstock]

My guess is we gambled on melligen, therefore not needing a partner.
Should have just repeated earlier work with porcine islets to get some attention.

[Jimmy Joe]

There will be major competition in this area. The world diabetes market is north of $250 billion. Plenty of room for a variety of answers. CiaB may well be one such treatment.

[Jameseypoo]

Encapsulation enters the Pharma industry mainstream

This article is similar, although it specifically mentions PMCB as well


https://www.biospectrumasia.com/analysis/26/10645/encapsulation-enters-the-pharma-industry-mainstream.html

"Early trials for the treatment of brain cancer using cells producing anti-angiogenic factors employed alginate as the encapsulation material (Read et al., 2001; Joki et al., 2001), but more recently a new material, cellulose sulphate, has been described which offers significant advantages over alginate in the areas of tolerability, large scale manufacture and freezing for storage and transport (Salmons et al., 2007). Cellulose sulphate encapsulation has been successfully used in two clinical trials for pancreatic cancer (Lohr et al., 2014) as well as in a clinical trial in dogs with spontaneously occurring mammary tumors (Michalowska et al., 2014). The encapsulation company Austrianova is currently producing under GMP conditions genetically modified cells encapsulated in cellulose sulphate for its U.S. partner PharmaCyte Biotech Inc., who will continue with late stage clinical trials using these encapsulated cells in combination with low dose chemotherapy with the aim of improving the anti-tumor effects of the chemotherapy whilst reducing the efficacious dose so that side effects are largely avoided (ref or PR)."